title: Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients.
abstract: OBJECTIVE
  This study aimed to evaluate the antiviral response and safety of tenofovir (TDF) versus entecavir (ETV) in treatment-naïve CHB patients.
  
  
  METHODS
  We performed a retrospective cohort study of treatment-naive CHB patients who were treated with TDF or ETV. We analyzed virologic, biochemical, and serologic responses at 3, 6, and 12 months.
  
  
  RESULTS
  A total of 107 patients (TDF group = 49, ETV group = 58) were included. Baseline characteristics were similar between the two groups. The estimated proportion of complete virologic response (CVR) in the TDF or ETV group was 44.9% versus 39.7% at 6 months and 89.6% versus 83.2% at 12 months, respectively (P = 0.991). Viral breakthrough was not observed in both groups. One patient in the TDF group and two patients in the ETV group experienced HBeAg loss, respectively (P = 0.657). High HBV DNA level at baseline was a significant negative predictor of virologic response by Cox regression analysis (P = 0.007). The safety profile was similar between the two groups. There was no case with serious adverse event.
  
  
  CONCLUSIONS
  Both TDF and ETV were effective in achieving CVR and had a favorable safety profile in treatment-naïve CHB patients. High viral load at baseline was a negative predictive factor of CVR.
authors.forename: Hyung Min
authors.initials: HM
authors.lastname: Yu
authors.affiliation: Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea, South Korea.
authors.forename: So Young
authors.initials: SY
authors.lastname: Kwon
authors.forename: Jiwan
authors.initials: J
authors.lastname: Kim
authors.forename: Hyun Ah
authors.initials: HA
authors.lastname: Chung
authors.forename: Se Woong
authors.initials: SW
authors.lastname: Kwon
authors.forename: Taek Gun
authors.initials: TG
authors.lastname: Jeong
authors.forename: Sang Hee
authors.initials: SH
authors.lastname: An
authors.forename: Gyung Won
authors.initials: GW
authors.lastname: Jeong
authors.forename: Seon Ung
authors.initials: SU
authors.lastname: Yun
authors.forename: Jae Ki
authors.initials: JK
authors.lastname: Min
authors.forename: Jeong Han
authors.initials: JH
authors.lastname: Kim
authors.forename: Won Hyeok
authors.initials: WH
authors.lastname: Choe
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D004279:DNA, Viral / Q000235:genetics; D005260:Female; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006513:Hepatitis B e Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology*; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000068698:Tenofovir / Q000009:adverse effects / Q000627:therapeutic use*; D019562:Viral Load / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D018894:Reverse Transcriptase Inhibitors; C413685:entecavir; D006147:Guanine; D000068698:Tenofovir